SG11202010006UA - Hemp extract for treatment of pain in animals - Google Patents

Hemp extract for treatment of pain in animals

Info

Publication number
SG11202010006UA
SG11202010006UA SG11202010006UA SG11202010006UA SG11202010006UA SG 11202010006U A SG11202010006U A SG 11202010006UA SG 11202010006U A SG11202010006U A SG 11202010006UA SG 11202010006U A SG11202010006U A SG 11202010006UA SG 11202010006U A SG11202010006U A SG 11202010006UA
Authority
SG
Singapore
Prior art keywords
pain
animals
treatment
hemp extract
hemp
Prior art date
Application number
SG11202010006UA
Inventor
Amanda Howland
Christian Kjaer
Michael Williams
Original Assignee
Ellevet Sciences
Amanda Howland
Christian Kjaer
Michael Williams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ellevet Sciences, Amanda Howland, Christian Kjaer, Michael Williams filed Critical Ellevet Sciences
Publication of SG11202010006UA publication Critical patent/SG11202010006UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/40Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
SG11202010006UA 2018-04-09 2019-04-09 Hemp extract for treatment of pain in animals SG11202010006UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862655170P 2018-04-09 2018-04-09
PCT/US2019/026631 WO2019199861A2 (en) 2018-04-09 2019-04-09 Hemp extract for treatment of pain in animals

Publications (1)

Publication Number Publication Date
SG11202010006UA true SG11202010006UA (en) 2020-11-27

Family

ID=68163314

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010006UA SG11202010006UA (en) 2018-04-09 2019-04-09 Hemp extract for treatment of pain in animals

Country Status (10)

Country Link
US (2) US20230110830A1 (en)
EP (1) EP3773528B1 (en)
JP (1) JP2021521277A (en)
CN (1) CN112969452A (en)
AU (1) AU2019251357B2 (en)
BR (1) BR112020020850A2 (en)
CA (1) CA3096842A1 (en)
MX (1) MX2020010603A (en)
SG (1) SG11202010006UA (en)
WO (1) WO2019199861A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210275556A1 (en) * 2018-07-02 2021-09-09 Companion Sciences. LLC Cannabidiol Combination Compositions
US11484487B1 (en) * 2018-07-23 2022-11-01 Robell Research, Inc. Gingivitis gum serum
US20230090094A1 (en) * 2019-07-02 2023-03-23 Ellevet Sciences Hemp extract for treatment of pain, cancer and epilepsy in animals
CN111956664A (en) * 2019-12-03 2020-11-20 云南汉盟制药有限公司 Composition for pets and application thereof
WO2021127749A1 (en) * 2019-12-24 2021-07-01 Cannadol Pharmaceuticals Ltd Compositions comprising terpenes and their use in the treatment or alleviation of pain or anxiety
WO2021226099A1 (en) * 2020-05-04 2021-11-11 Agronomed Management, Llc Topical anti-inflammatory cannabinoid compositions
IL299008A (en) * 2020-06-12 2023-02-01 Zelira Therapeutics Operations Pty Ltd Composition and method for treating chronic pain
US20220110888A1 (en) * 2020-10-09 2022-04-14 Charlotte's Web, Inc. Composition for the treatment of psoriasis
WO2023130161A1 (en) * 2022-01-10 2023-07-13 Dolce Cann Global Pty Ltd Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda) along with an additional active agent
WO2023130160A1 (en) * 2022-01-10 2023-07-13 Dolce Cann Global Pty Ltd Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda).
WO2023173060A1 (en) * 2022-03-10 2023-09-14 Portland Technology Holdings Llc Compositions comprising hemp extract and related treatment methods
KR102524364B1 (en) * 2022-10-24 2023-04-24 전북대학교산학협력단 Composition for preventing or treating periodontitis comprising cannabidiol and taurine

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10051427C1 (en) 2000-10-17 2002-06-13 Adam Mueller Process for the production of an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material and cannabis extracts
EP1482917B1 (en) 2002-02-01 2019-05-08 GW Pharma Limited Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
EP1559423A1 (en) * 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
CN1840051B (en) * 2006-01-23 2013-08-28 北京因科瑞斯生物制品研究所 Pain-stopping gel with musk and its preparation method
US8481085B2 (en) 2006-06-15 2013-07-09 Gw Pharma Limited Pharmaceutical compositions comprising cannabigerol
GB2448535A (en) 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450493A (en) 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors
EP2044935B1 (en) 2007-10-02 2011-01-05 Vivacell Biotechnology Espana S.L. A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
NL2006621C2 (en) * 2011-04-18 2012-10-22 Fytagoras B V New medical use for acidic cannabinoids.
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
CA2850570A1 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
US9254272B2 (en) 2011-11-30 2016-02-09 Sutter West Bay Hospitals Resorcinol derivatives
WO2013147965A1 (en) * 2012-03-28 2013-10-03 Freeman Keith Gerald Medical compositions, methods of making and using those compositions, and kits including those compositions
US20140256692A1 (en) * 2013-03-07 2014-09-11 Nicholas Adam Brockman Composition and Method for Alleviation of Pain and Inflammation
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
WO2015025312A1 (en) * 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
KR20160094950A (en) * 2013-10-31 2016-08-10 풀 스펙트럼 래버러토리즈, 리미티드 Terpene and cannabinoid formulations
CA2931486A1 (en) 2013-11-05 2015-05-14 Ardent Llc Sublingual cannabis dosage form and methods of making and using the same
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
US20160000843A1 (en) 2014-07-01 2016-01-07 MJAR Holdings, LLC High cannabidiol cannabis strains
BR112017003966A2 (en) 2014-08-25 2018-10-23 Full Spectrum Laboratories Ltd apparatus and methods for the simultaneous production of cannabinoid compounds
WO2016064987A1 (en) * 2014-10-21 2016-04-28 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
WO2016087649A2 (en) 2014-12-04 2016-06-09 Servicio Andaluz De Salud Use of cannabinoids as ceramide-generating anticancer agents in tumors of the hematopoietic and lymphoid tissues
JP2018505912A (en) 2014-12-12 2018-03-01 オーハイ エナジェティクス ピービーシー Microencapsulated cannabinoid composition
IL253664B (en) 2015-01-31 2022-09-01 Constance Therapeutics Inc Methods for preparation of cannabis oil extracts and compositions
AU2016215094B2 (en) * 2015-02-05 2019-09-26 Colorado Can Llc Purified CBD and CBDA, and methods, compositions and products employing CBD or CBDA
ES2860452T3 (en) 2015-02-16 2021-10-05 Apirx Pharmaceutical Usa Llc Cosmetic and topical compositions comprising cannabigerol and cannabidiol
US20170266153A1 (en) 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
EP3265081A4 (en) * 2015-03-02 2018-11-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
EP3294289A4 (en) 2015-05-13 2019-01-02 One World Cannabis Ltd Use of cannabis to treat fibromyalgia, methods and compositions thereof
BR112017025388A2 (en) 2015-05-28 2018-08-07 Tweed Inc. cannabis plants having modified expression of thca synthase
BR112018001310A2 (en) * 2015-07-22 2018-09-11 Phytopharma Int Ltd bee-ingestible compositions, methods of use thereof for the production of honey and honey produced by these
US10064950B2 (en) 2015-07-24 2018-09-04 Shabana Naheed Medication dispensing system
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2542797A (en) 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
EP3380096A4 (en) * 2015-11-24 2019-10-23 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
US9956174B1 (en) 2016-02-08 2018-05-01 Jeff Nordahl Packaged frozen cubes of cannabis juice purée with added decarboxylated cannabis material
GB2549277B (en) 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
CA3020798A1 (en) 2016-04-12 2017-10-19 Scott SCHANEVILLE Ingestible films having substances from hemp or cannabis
WO2017177261A1 (en) 2016-04-12 2017-10-19 Habi Pharma Pty Ltd Liposomal preparation and methods of treatment
LT6486B (en) * 2016-04-13 2018-01-10 UAB "SatiMed" The oleo gel composition and delivery system with active compounds from c. sativa and m. arvensis for reduction of inflamation and pain in deep tissues
CN106074465A (en) * 2016-06-14 2016-11-09 云南瑞酚生物科技有限公司 Cannabinol compounds application in preparation treatment gouty arthritis medicine
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-emulsifying compositions of cannabinoids
PE20230607A1 (en) * 2016-08-03 2023-04-13 Zelda Therapeutics Operations Pty Ltd CANNABIS COMPOSITION
EP3503875A4 (en) 2016-08-29 2020-06-24 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
CA3036636A1 (en) 2016-09-14 2018-03-22 Altria Client Services Llc Smoking device
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Dilutable formulations of cannbinoids and processes for their preparation
PE20200755A1 (en) * 2017-01-14 2020-07-27 Herbolea Biotech Srl EXTRACTION BASED ON LIPID ASSISTED BY ENZYMES AND STABILIZATION OF PHYTO-CANNABINOIDS AND TERPENES, AND PRODUCTS OBTAINED FROM THE SAME
WO2018175259A1 (en) * 2017-03-18 2018-09-27 Mcgarrah Steven M Pet food including cannabidiolic acid
WO2018175796A1 (en) 2017-03-24 2018-09-27 STAUFF, Deidra Skin care compositions and methods
WO2018187500A1 (en) 2017-04-05 2018-10-11 University Of Mississippi Isolation of pure cannabinoids from cannabis
CN110997006A (en) 2017-05-08 2020-04-10 因美制药公司 Ophthalmic drug delivery formulations
WO2018217803A2 (en) 2017-05-22 2018-11-29 Growblox Life Sciences L.L.C. Myrcene-containing complex mixtures targeting trpv1
WO2019003163A2 (en) 2017-06-28 2019-01-03 Buzzelet Development And Technologies Ltd. Terpene-enriched cannabinoid product for women health
JP7223744B2 (en) 2017-07-26 2023-02-16 ティージーエックス ソフト チュー エルエルシー Starch-free soft chews for veterinary use
US10597348B1 (en) 2017-08-21 2020-03-24 Jeff Nordahl Infusing raw cannabinoids into food oil
US11484510B2 (en) 2017-08-28 2022-11-01 Apirx Pharmaceutical Usa, Llc Method to treat vitiligo
US20190060250A1 (en) 2017-08-28 2019-02-28 Axim Biotechnologies, Inc. Method to treat psoriasis
US10272051B2 (en) 2017-08-28 2019-04-30 Axim Biotechnologies, Inc. Method to treat atopic dermatitis
EP3449992A1 (en) 2017-09-04 2019-03-06 Bionorica Ethics GmbH Recovery of acidic cannabinoids from plant material
AU2018330807A1 (en) 2017-09-08 2020-03-05 Scicann Therapeutics Inc. Compositions comprising a cannabinoid and spilanthol
US10654823B2 (en) 2017-09-09 2020-05-19 Scientific Holdings, Llc Transparent glassy cannabinoid compositions
US11473096B2 (en) 2017-10-03 2022-10-18 The Regents Of The University Of Colorado, A Body Corporate Method for differentiating cannabis plant cultivars based on cannabinoid synthase paralogs
WO2019071302A1 (en) 2017-10-09 2019-04-18 The University Of Sydney Methods and compositions for treating or preventing seizures
MX2020003661A (en) 2017-11-30 2020-08-03 Canopy Growth Corp Liquid dosage forms, methods of making and use.
WO2019113497A1 (en) 2017-12-08 2019-06-13 Biotech Institute LLC High cannabigerol cannabis plants, methods of producing and methods of using them
CA3090359A1 (en) 2018-02-15 2019-08-22 Syqe Medical Ltd. Method and inhaler for providing two or more substances by inhalation
WO2019159176A1 (en) 2018-02-18 2019-08-22 Scicann Therapeutics Inc. Compositions and methods for treatment of neurodegenerative diseases
US20190297821A1 (en) 2018-03-28 2019-10-03 Jack Hempicine Llc Cross-hybridization of distinct homozygous cannabis plants to produce consistent early flowering seeds
WO2019195752A1 (en) 2018-04-05 2019-10-10 Canopy Holdings, LLC Hemp powder
WO2019210401A1 (en) 2018-05-01 2019-11-07 Willinsky Michael Novel anti-inflammatory, analgesic, anti-depressant cannabinoid and methods related to manufacture of same
WO2019227167A1 (en) 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments
US10695316B2 (en) 2018-07-03 2020-06-30 Virgil Macaluso Methods of heating cannabis plant material
US20200288659A1 (en) 2018-07-12 2020-09-17 Jack Hempicine Llc Production of cannabis plants and seeds using a targeted allele
US20200015440A1 (en) 2018-07-12 2020-01-16 Jack Hempicine Llc Production of cannabis plants and seeds using a targeted allele
US20200015441A1 (en) 2018-07-12 2020-01-16 Jack Hempicine Llc Production of cannabis plants and seeds using a targeted allele
PT3823962T (en) 2018-07-19 2023-04-26 Al&Am Pharmachem Ltd Process for purification of cannabinoic acids from plant material extract
WO2020028875A1 (en) 2018-08-02 2020-02-06 DIVIOS, LLC (a California Limited Liability Company) Sunscreen composition comprising cannabis extracts
WO2020044123A1 (en) 2018-08-27 2020-03-05 Emerald Health Therapeutics Canada Inc. Therapeutic combinations of boswellia extract and cannabinoids
WO2020044118A1 (en) 2018-08-27 2020-03-05 Emerald Health Therapeutics Canada Inc. Improved cannabinoid bioavailability
MX2021002719A (en) 2018-09-05 2021-09-23 Nemus Bioscience Inc Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains.
US10696646B2 (en) 2018-10-18 2020-06-30 Taba Ip, Llc Purification of cannabinoids from crude cannabis oil
WO2020084427A1 (en) 2018-10-23 2020-04-30 Radient Technologies Innovations Inc. Temperature control for active compound extraction
WO2020123383A1 (en) 2018-12-10 2020-06-18 Natural Extraction Systems, LLC Compositions with novel cannabinoid and terpene profiles
EP3893868A4 (en) 2018-12-12 2022-08-10 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Compositions and methods for the treatment of cutaneous t cell lymphoma (ctcl)
WO2020165902A1 (en) 2019-02-15 2020-08-20 Plantbiosis Ltd. Method for synthesis of cannabis products
NL2022616B1 (en) 2019-02-21 2020-09-18 Patrick Alexander Unger Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia

Also Published As

Publication number Publication date
WO2019199861A3 (en) 2020-07-23
AU2019251357A1 (en) 2020-12-03
BR112020020850A2 (en) 2021-01-19
US20230110830A1 (en) 2023-04-13
CN112969452A (en) 2021-06-15
CA3096842A1 (en) 2019-10-17
EP3773528A4 (en) 2022-01-05
WO2019199861A2 (en) 2019-10-17
JP2021521277A (en) 2021-08-26
AU2019251357B2 (en) 2023-10-05
EP3773528B1 (en) 2024-01-10
MX2020010603A (en) 2021-02-02
EP3773528A2 (en) 2021-02-17
US20220211790A1 (en) 2022-07-07
US11712456B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
SG11202010006UA (en) Hemp extract for treatment of pain in animals
IL268138A (en) Combinations of cabozantinib and atezolizumab to treat cancer
IL259809A (en) Apparatus and cosmetic method for cosmetic treatment of human mucosal tissue
IL279748A (en) Composition and method for treating pain
EP3648841C0 (en) Apparatus for internal organ, injury and pain treatment
EP3993780A4 (en) Hemp extract for treatment of pain, cancer and epilepsy in animals
HK1249865B (en) Treatment of pain
IL282473A (en) Cosmetic method and therapeutic use for fat reduction
IL272036A (en) Methods and compositions for treatment of pain using capsaicin
IL269743A (en) Methods and compositions for treating retina-associated disease using ccr3-inhibitors
PL3326637T3 (en) Use of mangosteen rind extract in preparation of medicine for treating skin diseases
SG11201705524SA (en) Compositions and methods for the treatment of inflammation and pain
ZA202007320B (en) Compounds for pain treatment, compositions comprising same, and methods of using same
EP3621619C0 (en) Compounds and methods for treatment of visceral pain
IL280638A (en) Fat tissue treatment
IL282685A (en) Methods of treatment using anti-cd123 immunoconjugates
IL277962A (en) Methods of treating neuropathic pain
IL268111A (en) Methods of treating pain
IL247369A0 (en) Compositions and methods for treatment of bone associated diseases
IL246608A0 (en) Compositions and methods for treating heart disease
ZA201904327B (en) Treatment of skin conditions
ZA201904326B (en) Treatment of joint pain
GB201720401D0 (en) Means and methods to treat torsin related neurologicl diseases
GB201720505D0 (en) Methods for treatment of neuropathic pain
GB201811911D0 (en) Treatment of disease